Maxime Boussageon
Overview
Explore the profile of Maxime Boussageon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dessemon J, Perol O, Chauvel C, Noelle H, Coudon T, Grassot L, et al.
Front Public Health
. 2024 Feb;
11:1306455.
PMID: 38328545
Introduction: Residential exposure is estimated to be responsible for nearly 10% of lung cancers in 2015 in France, making it the second leading cause, after tobacco. The Auvergne-Rhône-Alpes region, in...
2.
Dehem A, Mazieres J, Chour A, Guisier F, Ferreira M, Boussageon M, et al.
Lung Cancer
. 2023 Oct;
186:107393.
PMID: 37839252
Background: NRAS mutations are observed in less than 1% of non-small cell lung cancer (NSCLC). Clinical data regarding this rare subset of lung cancer are scarce and response to systemic...
3.
Bouhamama A, Leporq B, Faraz K, Foy J, Boussageon M, Perol M, et al.
Front Radiol
. 2023 Jul;
3:1168448.
PMID: 37492391
Introduction: In this study, we aim to build radiomics and multiomics models based on transcriptomics and radiomics to predict the response from patients treated with the PD-L1 inhibitor. Materials And...
4.
Noelle H, Perol O, Perol M, Avrillon V, Belladame E, Fayette J, et al.
Lung Cancer
. 2023 Mar;
179:107182.
PMID: 37001440
Objective: This study investigated the association between occupational asbestos exposure (OAE) and survival in patients with histologically confirmed lung cancer (LC). Methods: This monocentric study was conducted in the Comprehensive...
5.
Boussageon M, Swalduz A, Chouaid C, Bylicki O
BioDrugs
. 2022 Nov;
37(1):121.
PMID: 36401075
No abstract available.
6.
Foy J, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, et al.
Data Brief
. 2022 Sep;
44:108556.
PMID: 36111282
Identification of tumors harboring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who...
7.
Foy J, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, et al.
Eur J Cancer
. 2022 Aug;
174:287-298.
PMID: 36038492
Introduction: Identification of tumours harbouring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC)...
8.
Ortiz-Cuaran S, Swalduz A, Foy J, Marteau S, Morel A, Fauvet F, et al.
Eur J Cancer
. 2022 May;
169:106-122.
PMID: 35550950
Introduction: Epithelial-to-mesenchymal transition (EMT) is associated with tumor aggressiveness, drug resistance, and poor survival in non-small cell lung cancer (NSCLC) and other cancers. The identification of immune-checkpoint ligands (ICPLs) associated...
9.
Boussageon M, Swalduz A, Chouaid C, Bylicki O
BioDrugs
. 2022 Feb;
36(2):137-151.
PMID: 35147894
Treatment of metastatic non-small-cell lung cancers (NSCLCs) has long been based on cytotoxic chemotherapy. Immune checkpoint inhibitors (ICIs), notably monoclonal antibodies directed against programmed cell death protein-1 (PD-1) or its...
10.
Valet O, Swalduz A, Boussageon M, Buisson A, Avrillon V, Mastroianni B, et al.
JTO Clin Res Rep
. 2021 Sep;
2(6):100192.
PMID: 34590033
Molecular sequencing after highly potent targeted gene inhibitors have suggested resistant tumors can display substantial heterogeneity. Among these various mechanisms of resistance, secondary mutations on targetable oncogenes have been identified....